Among the eight co-expressed genes related to NSCLC, IL11RA, NCAPD2, and MLC1 passed both the SMR analysis and HEIDI tests (PSMR < 0.05 and PHEIDI > 0.05), further substantiating the potential of IL11RA, NCAPD2, and MLC1 as prospective therapeutic targets for NSCLC (Table 5, Figure 5). This evidence concerns the gene NCAPD2 and non-small cell lung carcinoma.